Hong Kong drug regulator centre to launch by year-end
AM730 · 6 SOURCESabout 2 hours ago6 MIN
Summary
Hong Kong’s Centre for Drug and Medical Device Regulation is expected to be established by the end of this year, as the government continues rolling out a first-tier approval regime for innovative medicines. Newly appointed Director of Drug and Medical Device Regulation Li Zili (李自力) said the centre aims to build comprehensive independent review capacity, win international trust through rigorous and transparent regulation, and adopt a strategic role tailored to Hong Kong rather than copying any overseas regulator. He said the centre would use a cross-disciplinary scientific review team centred on clinical assessment, while also making effective use of assessments by other regulators. Patient advocates and industry figures said they hope the new body can speed access to rare-disease, oncology, gene-therapy and cell-therapy products, while reducing patients’ financial burden and strengthening Hong Kong’s international standing
Key Points
- Li said the new centre will not be a “mini FDA”, but a Hong Kong-specific regulator focused on public health protection and medical innovation.
- He outlined three goals: full independent assessment capability, international trust built through scientific transparency, and a distinctive strategic role linking mainland China and global markets.
- The centre plans a cross-professional scientific review team led by clinical assessment, covering 12 specialties including statistics, pre-clinical toxicology and drug quality.
- Hong Kong began phasing in first-tier approval for new drug registration from late March 2026, with full implementation targeted for 2030
- Director of Health Ronald Lam Man-kin said more than 20 applications were received for the director post, with over 40% from outside Hong Kong.
Why It Matters
For patients, especially those with serious or rare diseases, the centre could widen access to suitable innovative medicines if Hong Kong can combine safety, efficacy and faster regulatory pathways. For the city, officials and industry are positioning the regulator as both a bridge for mainland-developed drugs to reach overseas markets and a step toward greater international recognition of Hong Kong’s life and health technology ecosystem.